Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Holding ORMP?
Track your performance easily
ORMP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.00 - $3.67
Previous Close$2.31
Volume106.95K
Average Volume (3M)97.06K
Market Cap
$93.12M
Enterprise Value-$6.89M
Total Cash (Recent Filing)$99.56M
Total Debt (Recent Filing)$464.00K
Price to Earnings (P/E)21.2
Beta0.70
Next Earnings
Jul 10, 2024EPS Estimate
$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding40,312,069
10 Day Avg. Volume128,628
30 Day Avg. Volume97,057
Standard Deviation0.29
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)69.19
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.14
Enterprise Value/Ebitda-0.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Oramed Pharm News
PremiumCompany Announcements
Oramed Pharmaceuticals Reinforces Scilex Financial Ties
PremiumCompany Announcements
Oramed Pharm Names Avraham Gabay as New CFO
PremiumCompany Announcements
Oramed Pharmaceuticals Seeks New CFO After Resignation
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOramed intends to initiate a U.S. Phase 3 oral insulin trial under a differentiated protocol that aligns with this positive data.
InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Bears Say
Clinical TrialsThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
Market ValueThe evolution of the COVID-19 pandemic remains uncertain, with the possibility existing that novel vaccine solutions may have little to no commercial value.
Product PortfolioOramed still possesses a portfolio of additional assets beyond ORMD-0801 in T2D, but the candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.
---
Ownership Overview
15.30% Insiders
0.10% Mutual Funds
11.53% Other Institutional Investors
72.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORMP FAQ
What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was $2.00 and its highest was $3.67 in the past 12 months.
What is Oramed Pharmaceuticals’s market cap?
Currently, no data Available
When is Oramed Pharmaceuticals’s upcoming earnings report date?
Oramed Pharmaceuticals’s upcoming earnings report date is Jul 10, 2024 which is 136 days ago.
How were Oramed Pharmaceuticals’s earnings last quarter?
Oramed Pharmaceuticals released its earnings results on Jan 11, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Oramed Pharmaceuticals overvalued?
According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued.
Does Oramed Pharmaceuticals pay dividends?
Oramed Pharmaceuticals does not currently pay dividends.
What is Oramed Pharmaceuticals’s EPS estimate?
Oramed Pharmaceuticals’s EPS estimate is $0.01.
How many shares outstanding does Oramed Pharmaceuticals have?
Oramed Pharmaceuticals has 40,312,070 shares outstanding.
What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
Oramed Pharmaceuticals reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -0.4%.
Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
Currently, no hedge funds are holding shares in ORMP
---
Oramed Pharm Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.94%
12-Months-Change
Fundamentals
Return on Equity
2.92%
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Company Description
Oramed Pharmaceuticals
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.
---
ORMP Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---